<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title>Frontiers in Physiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Physiol.</abbrev-journal-title>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphys.2020.00621</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Regulatory T Cells as a Novel Candidate for Cell-Based Therapy in Kidney Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lu</surname> <given-names>Junyu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/948177/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname> <given-names>Jianfeng</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname> <given-names>Menghua</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname> <given-names>Chun</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Zhengzhao</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liao</surname> <given-names>Pinhu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/948062/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>The First Clinical Medical College of Jinan University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Intensive Care Unit, The Second Affiliated Hospital of Guangxi Medical University</institution>, <addr-line>Nanning</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Emergency Medicine, The Second Affiliated Hospital of Guangxi Medical University</institution>, <addr-line>Nanning</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Cardiology and Endocrinology, The People&#x2019;s Hospital of Guangxi Zhuang Autonomous Region</institution>, <addr-line>Nanning</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Emergency Medicine, The First Affiliated Hospital of Guangxi Medical University</institution>, <addr-line>Nanning</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Natalia Lopez-Andres, NavarraBiomed, Spain</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Bo Wang, Monash University, Australia; Hong Jiang, Zhejiang University, China</p></fn>
<corresp id="c001">&#x002A;Correspondence: Junyu Lu, <email>junyulu@gxmu.edu.cn</email></corresp>
<corresp id="c002">Pinhu Liao, <email>liaopinhu@163.com</email></corresp>
<fn fn-type="other" id="fn002"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
<fn fn-type="other" id="fn004"><p>This article was submitted to Renal and Epithelial Physiology, a section of the journal Frontiers in Physiology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>621</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>04</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>05</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2020 Lu, Zhang, Chen, Chen, Li and Liao.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Lu, Zhang, Chen, Chen, Li and Liao</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Kidney disease is a significant health concern worldwide. Ineffective treatment can lead to disastrous consequences, such as organ failure and death. Research has turned to cell-based therapy, but has yet to produce an effective and reliable treatment for kidney disease. To address this problem, we examined four datasets of gene expression profiles from diseased and healthy kidney tissue in humans, mice, and rats. Differentially expressed genes (DEGs) were screened and subjected to enrichment analyses. Up-regulated genes in diseased kidney tissue were significantly enriched in pathways associated with regulatory T cells (Tregs). Analysis with the xCell tool showed that Tregs were generally increased in diseased kidney tissue in all species. To validate these results <italic>in vivo</italic>, kidneys were removed from mice with Adriamycin-induced nephropathy, and histology confirmed increase of Tregs. Furthermore, Tregs were adoptively transferred from healthy mice into mice with kidney injury, restoring normal structure to the damaged kidneys. Treg cells that were co-cultured with M2c macrophages exhibited up-regulation of chemokine receptors CCR2, CCR5, CCR7, CD62L, and CX3CR1. This may be the mechanism by which M2c cells enhance the migration of Tregs to the site of inflammation. We propose that Tregs may be an effective, novel candidate for cell-based therapy in pre-clinical kidney injury models.</p>
</abstract>
<kwd-group>
<kwd>regulatory T cell</kwd>
<kwd>Treg</kwd>
<kwd>M2c macrophage</kwd>
<kwd>cell-based therapy</kwd>
<kwd>kidney injury</kwd>
</kwd-group><counts>
<fig-count count="6"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="36"/>
<page-count count="10"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>Kidney disease has become a significant global public health problem, with incidence and mortality rates increasing in recent decades (<xref ref-type="bibr" rid="B18">Lentine et al., 2017</xref>; <xref ref-type="bibr" rid="B11">Fraser and Roderick, 2019</xref>). Renal failure is associated with age (<xref ref-type="bibr" rid="B15">Kazancioglu, 2013</xref>) and it affects both men and women (<xref ref-type="bibr" rid="B13">Iseki, 2005</xref>). Acute kidney injury (AKI) can increase the risk of chronic kidney disease (CKD), which can eventually lead to end-stage renal disease (<xref ref-type="bibr" rid="B6">Chawla and Kimmel, 2012</xref>). The prevalence of AKI is approximately 1.9% in all hospitalized patients and more than 40% in the intensive care unit (<xref ref-type="bibr" rid="B19">Liangos et al., 2006</xref>) while the prevalence of CKD is estimated to be 8&#x2013;16% worldwide (<xref ref-type="bibr" rid="B14">Jha et al., 2013</xref>). Though kidney injury is relatively common, there is no specific treatment for it, and most therapies target the underlying disease. Thus, treatment for kidney injury remains a significant challenge for clinicians (<xref ref-type="bibr" rid="B3">Bagshaw and Bellomo, 2007</xref>; <xref ref-type="bibr" rid="B14">Jha et al., 2013</xref>) and new effective therapeutic strategies are urgently need.</p>
<p>Cell-based regenerative therapy has been extensively evaluated as a treatment for kidney injury in animal models (<xref ref-type="bibr" rid="B10">Fang et al., 2012</xref>; <xref ref-type="bibr" rid="B30">Van Koppen et al., 2012</xref>; <xref ref-type="bibr" rid="B36">Zhu et al., 2013</xref>). Thus far, mesenchymal stem cells and endothelial progenitor cells have been most studied (<xref ref-type="bibr" rid="B22">Papazova et al., 2015</xref>). However, a clinical trial giving allogenic mesenchymal stem cells to patients with AKI did not accelerate functional recovery (<xref ref-type="bibr" rid="B28">Swaminathan et al., 2018</xref>). Therefore, investigating other candidate cell types is necessary. It is widely recognized that kidney injury is closely related to the immune system and immune cells (<xref ref-type="bibr" rid="B25">Sato and Yanagita, 2018</xref>) yet this avenue has not been thoroughly evaluated. We hypothesized that immune cells may be potential candidates for cell-based therapy against kidney injury. Indeed, we show in the present study that the proportion of regulatory T cells (Tregs) was higher in injured kidney tissue than in healthy kidney tissue. We confirmed these findings in mice with Adriamycin-induced nephropathy, suggesting that adoptive transfer of Tregs can improve injury. In addition, we observed <italic>in vitro</italic> that M2c macrophages up-regulate chemokine receptors in Tregs, which may recruit Tregs to sites of inflammation in injured kidney.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2.SS1">
<title>Prediction of Genes Associated With AKI or CKD</title>
<p>We downloaded the following four gene expression datasets from the Gene Expression Omnibus (GEO) database<sup><xref ref-type="fn" rid="footnote1">1</xref></sup> : (1) GSE12682 (<xref ref-type="bibr" rid="B26">Si et al., 2009</xref>) comparing human kidney tissue between 29 healthy controls and 23 CKD samples, measured by the Affymetrix Human Genome U133A 2.0 Array (Affymetrix; Thermo Fisher Scientific, Waltham, MA, United States); (2) GSE12683 (<xref ref-type="bibr" rid="B26">Si et al., 2009</xref>) comparing Balb/c mouse kidney tissue between 10 healthy controls and 10 samples with AKI, measured by Affymetrix Mouse Genome 430A 2.0 Array; (3) GSE102513 (<xref ref-type="bibr" rid="B31">Vandenbussche et al., 2018</xref>) comparing CD-1 mouse kidney tissue between four healthy controls and four samples CKD induced by Tacrolimus (1 mg/kg/day for 28 days), measured by the Agilent-028005 SurePrint G3 Mouse GE 8x60K Microarray; and (4) GSE85957 (<xref ref-type="bibr" rid="B23">Pavkovic et al., 2014</xref>) comparing <italic>Rattus norvegicus</italic> (brown rat) kidney tissue samples between 19 healthy controls and 38 rats with kidney disease induced with 1 or 3 mg/kg cisplatin. In this last dataset, tissue was collected on days 3, 5, 8, and 26, and gene expression was measured using the Rat Genome 230 2.0 Array.</p>
<p>If one gene matched multiple probes, the average value of all probes was calculated as the expression of the corresponding gene. All sample collection and experimentation procedures were approved by the Guangxi Medical University Ethics Committee.</p>
</sec>
<sec id="S2.SS2">
<title>Screening of Differentially Expressed Genes (DEGs) and Functional Enrichment Analysis</title>
<p>Differentially expressed genes (DEGs) between healthy control and diseased human kidney tissue were identified using the <italic>limma</italic> package (<xref ref-type="bibr" rid="B24">Ritchie et al., 2015</xref>) in R from dataset GSE12682. Differential threshold was calculated based on two criteria: false discovery rate (FDR) <italic>P</italic>-value &#x003C; 0.05 and | log<sub>2</sub>(fold change)| &#x003E; 1. The <italic>ClusterProfiler</italic> package (<xref ref-type="bibr" rid="B33">Yu et al., 2012</xref>) in R was used to assess enrichment in biological processes (BPs) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Gene set enrichment was analyzed using the JAVA program<sup><xref ref-type="fn" rid="footnote2">2</xref></sup> based on MSigDB immunologic signatures (<italic>c7.all.v6.2.symbols.gmt</italic>) (<xref ref-type="bibr" rid="B12">Godec et al., 2016</xref>). Gene sets with a NOM <italic>P</italic>-value &#x003C; 0.05 after performing 1000 permutations were considered to be significantly enriched (<xref ref-type="bibr" rid="B27">Subramanian et al., 2005</xref>).</p>
</sec>
<sec id="S2.SS3">
<title>Immune Cell Enrichment Analysis</title>
<p>We used xCell web tool<sup><xref ref-type="fn" rid="footnote3">3</xref></sup> (<xref ref-type="bibr" rid="B2">Aran et al., 2017</xref>) with Charoentong signature (<xref ref-type="bibr" rid="B5">Charoentong et al., 2017</xref>) to generate cell enrichment scores based on gene signature profiles. Then these data were used to quantify immune cell proportions in all four datasets. Enrichment scores were compared using Student&#x2019;s <italic>t</italic>-test, and <italic>P</italic> &#x003C; 0.05 was considered to indicate a significant difference.</p>
</sec>
<sec id="S2.SS4">
<title>Mouse Model of Kidney Injury</title>
<p>Animal experiments were approved by the Guangxi Medical University Ethics Committee. C57BL/six mice (8 weeks old, 20 &#x00B1; 2 g) were purchased from the Experimental Animal Center of Guangxi Medical University. Mice were randomly divided into a control group (<italic>n</italic> = 27) and a treatment group (<italic>n</italic> = 27). The treatment group received 10.5 mg/kg Adriamycin (Zhejiang Hisun Pharmaceutical, Taizhou, China) three times per week for 2 weeks via the tail vein (<xref ref-type="bibr" rid="B20">Lu et al., 2013</xref>). The control group received injections of physiological saline via the tail vein. Urine was collected for 16 h overnight on day 27 for measurement of urinary protein. Blood was obtained on day 28 for measurement of serum creatinine and creatinine clearance. All urine and blood specimens were analyzed using automated analyzers at the Experimental Animal Center of Guangxi Medical University. Animals were sacrificed using cervical dislocation on day 28, and kidneys and spleens were removed for further study.</p>
</sec>
<sec id="S2.SS5">
<title>Preparation of Cell Suspensions</title>
<p>Kidneys were perfused with saline before removal, cut into 1&#x2013;2 mm<sup>3</sup> pieces and digested in Dulbecco&#x2019;s modified Eagle medium (DMEM) containing 1 mg/ml collagenase IV (Sigma&#x2013;Aldrich) and 100 mg/ml DNase I (Roche) for 40 min at 37&#x00B0;C with intermittent agitation. The digested cell suspension was then passed through a 40-&#x03BC;m cell strainer. Mononuclear cells were separated using 1.077 g/ml NycoPrep gradient (Axis-Shield, Oslo, Norway). Spleens from C57BL/6 mice were also isolated, minced, and digested for 30 min at 37&#x00B0;C in RPMI 1640 containing 1 mg/ml collagenase D and 100 mg/ml DNase I (both from Roche). The digested cell suspension was passed through a 40-&#x03BC;m cell strainer.</p>
</sec>
<sec id="S2.SS6">
<title>Flow Cytometry and Cell Sorting</title>
<p>Single-cell suspensions from kidney were subjected to magnetic bead separation, and CD3+ cells were purified using the CD3+ T cell kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The surface of CD3+ cells was labeled with antibodies against CD25 and FOXP3 (BD Accuri C6, United States). Double-positive cells were considered Tregs and were sorted using a flow cytometer (BD Accuri C6, United States) according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="S2.SS7">
<title>Mouse Model of Adoptive Cell Transfer</title>
<p>Tregs were extracted from spleens of healthy C57BL/six mice, and single-cell suspensions were prepared as in Section &#x201C;Preparation of Cell Suspensions.&#x201D; Cells were incubated <italic>in vitro</italic> in RPMI 1640 medium and allowed to proliferate for 7 days. Approximately 1.2 &#x00D7; 10<sup>6</sup> Tregs were injected via the tail vein into mice on day 5 after Adriamycin administration.</p>
</sec>
<sec id="S2.SS8">
<title>Tissue Histology and Immunofluorescence</title>
<p>All mice were sacrificed on day 28. Coronal sections of renal tissue were stained with rat anti-mouse CD103 antibody (M290, 1:200) and hamster anti-mouse CD11c antibody (N418, 1:100), then incubated with AF488-conjugated goat anti-rat IgG or AF546-conjugated goat anti-hamster IgG antibody (both 1:500). Tissue sections were analyzed on an inverted fluorescence microscope (BX50, Olympus). Consecutive sections from kidney cortex to kidney medulla were photographed.</p>
</sec>
<sec id="S2.SS9">
<title><italic>In vitro</italic> Co-cultures</title>
<p>Bone marrow from the femurs of C57BL/6 mice was harvested and triturated with sterile syringes, and the resulting cell suspension was filtered through 40-&#x03BC;m nylon mesh. Approximately 2 &#x00D7; 10<sup>6</sup> cells were incubated in RPMI 1640 containing 50 ng/ml granulocyte-macrophage colony stimulating factor (GM-CSF) at 37&#x00B0;C for 10 days. The adherent marrow-derived macrophages (M0) were rinsed three times in RPMI 1640 medium and then incubated in RPMI 1640 medium containing both IL-10 and TGF-&#x03B2; (10 ng/ml each) for 4 days to become M2c macrophages (<xref ref-type="bibr" rid="B20">Lu et al., 2013</xref>).</p>
<p>For co-culture experiments, M2c macrophages (1 &#x00D7; 10<sup>6</sup> cells/ml) were plated in six-well plates with 1.5 ml of Tregs (1 &#x00D7; 10<sup>6</sup> cells/ml). Co-cultures were incubated for 24 h at 37&#x00B0;C and 5% CO<sub>2</sub>. Control cultures contained only Tregs. After 24 h, the floating Tregs were collected, washed in RPMI 1640, and used in subsequent experiments.</p>
<sec id="S2.SS9.SSS1">
<title>PCR Array and Quantitative PCR (qPCR)</title>
<p>Total RNA was extracted from control and co-cultured Tregs using the TRIzol RNeasy kit (Invitrogen, Shanghai, China), then reverse-transcribed using the Superscript IV reverse transcription Kit (Invitrogen). Quantitative PCR was performed using the SYBR qPCR (Invitrogen) master mix according to the manufacturer&#x2019;s instructions. The primer list is shown in <xref ref-type="supplementary-material" rid="TS1">Supplementary Table S1</xref>.</p>
</sec>
<sec id="S2.SS9.SSS2">
<title>Western Blotting</title>
<p>Total protein was extracted from control and co-cultured Tregs using 200 &#x03BC;L ice-cold RIPA lysis buffer (catalog no. R0010, Solarbio, Beijing, China) at 4&#x00B0;C for 2 min and centrifuged. The supernatant was collected, protein concentration was estimated using a BCA kit (Solarbio, Beijing, China), and an equal amount of total protein in each sample was mixed with 5 &#x03BC;l of 5&#x00D7; SDS buffer and 2 &#x03BC;l of reducing agent (Invitrogen), then boiled at 70&#x00B0;C for 10 min. Samples were loaded onto a sodium dodecyl sulfate-polyacrylamide gel (8&#x2013;12% gradient), then transferred onto polyvinylidene fluoride membranes. Membranes were immunoblotted using antibodies (Abcam, Cambridge, United Kingdom) against the following proteins: GADPH (catalog no. ab9484), CCR2 (ab203128), CCR7 (ab32527), CCR8 (ab63772), CD62L (ab264045), and CX3CR1 (ab8021). The secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit IgG H&#x0026;L (ab205718). GADPH protein was used as the internal control. Bands were developed using the ECL Western Blotting Analysis System (Amersham, Sweden) and visualized with FluorChem E ProteinSimple (ProteinSimple, United States).</p>
</sec>
</sec>
<sec id="S2.SS10">
<title>Statistical Analysis</title>
<p>Statistical tests included the unpaired, two-tailed <italic>t</italic>-test using Welch&#x2019;s correction for unequal variances and one-way ANOVA with Tukey&#x2019;s multiple comparisons test. Statistical analyses were performed using Prism software (version 5, GraphPad) and R software (version 3.5.3). Results were expressed as mean &#x00B1; SEM. Differences associated with <italic>P</italic> &#x003C; 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<p>The study workflow is presented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>The work flow of the present study. KEGG, Kyoto Encyclopedia of Genes and Genomes.</p></caption>
<graphic xlink:href="fphys-11-00621-g001.tif"/>
</fig>
<sec id="S3.SS1">
<title>Immune System-Related Genes Are Up-Regulated After Kidney Injury</title>
<p>In human kidney tissue (GSE12682), we found a total of 345 DEGs by comparing healthy control tissue with CKD tissue (<xref ref-type="fig" rid="F2">Figure 2A</xref>), of which 123 genes were up-regulated and 222 down-regulated. The down-regulated genes were enriched in various renal system development-related BPs and KEGG pathways (<xref ref-type="supplementary-material" rid="TS2">Supplementary Tables S2</xref>, <xref ref-type="supplementary-material" rid="TS3">S3</xref>), whereas up-regulated genes were immune-related (<xref ref-type="fig" rid="F2">Figures 2B,C</xref>). Although no DEGs were identified in Balb/c mice (GSE12683) using the initial threshold (FDR <italic>P</italic> &#x003C; 0.05 and | log<sub>2</sub>(fold change)| &#x003E; 1), using a less stringent threshold (<italic>P</italic> &#x003C; 0.05) identified 660. These included 330 up-regulated genes enriched in various immune-related BPs (<xref ref-type="fig" rid="F2">Figure 2E</xref>). These results suggest that genes of the immune system are activated in injured kidney, and that identification of immune cells associated with these up-regulated genes may provide candidate therapeutic targets against kidney injury.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p><bold>(A)</bold> Volcano plot of the genes differentially expressed between chronic kidney disease tissue and healthy kidney tissue from humans (dataset GSE12682). Red indicates that a gene is up-regulated in chronic kidney disease, while blue indicates that it is down-regulated. <bold>(B)</bold> The 15 most significantly enriched biological processes from the up-regulated genes in GSE12682. <bold>(C)</bold> Enriched KEGG pathways for the up-regulated genes in GSE12682. <bold>(D)</bold> The five most significantly enriched gene sets in chronic kidney disease in GSE12682. <bold>(E)</bold> The 15 most significantly enriched biological processes for the up-regulated genes from Balb/c mice (dataset GSE12683). <bold>(F)</bold> The five most significantly enriched gene sets in Adriamycin-induced kidney injury in GSE12683.</p></caption>
<graphic xlink:href="fphys-11-00621-g002.tif"/>
</fig>
</sec>
<sec id="S3.SS2">
<title>Tregs Enriched in Injured Kidney</title>
<p>Gene set enrichment analysis confirmed that among the up-regulated immune-associated gene sets, those associated with Tregs were significantly enriched in both human CKD tissues (<xref ref-type="fig" rid="F2">Figure 2D</xref>) and mouse AKI tissues (<xref ref-type="fig" rid="F2">Figure 2F</xref>). Extraction of genetic profiles associated with different immune cells from all datasets and scoring them for enrichment (<xref ref-type="fig" rid="F3">Figure 3A</xref> and <xref ref-type="supplementary-material" rid="TS4">Supplementary Table S4</xref>) further confirmed Tregs to be more abundant in diseased kidney tissue than in healthy control tissue from humans, mice, or rats, regardless of the cause of tissue injury (<xref ref-type="fig" rid="F3">Figures 3B&#x2013;F</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p><bold>(A)</bold> Principal component analysis showed a significant difference in the immune cell population between chronic kidney disease tissue and healthy kidney tissue in humans (dataset GSE12682). <bold>(B)</bold> Heatmap depicting abundance of different immune cell types between chronic kidney disease and healthy kidney in GSE12682. Enrichment analysis of Treg-related genes was calculated and numbers of cells extrapolated for <bold>(C)</bold> chronic kidney disease compared to healthy kidney in humans (GSE12682), <bold>(D)</bold> Adriamycin-induced kidney injury compared to healthy kidney in Balb/c mice (GSE12683), and <bold>(E)</bold> cisplatin-induced kidney injury compared to healthy kidney in rat (GSE85957). &#x002A;<italic>P</italic> &#x003C; 0.05 versus control. <bold>(F)</bold> Tacrolimus-induced kidney injury compared to healthy kidney in CD-1 mice (GSE102513). C1, 1 mg/kg cisplatin; C3, 3 mg/kg cisplatin; var., variance; CTL, control; TAC, tacrolimus.</p></caption>
<graphic xlink:href="fphys-11-00621-g003.tif"/>
</fig>
</sec>
<sec id="S3.SS3">
<title>Tregs Are Increased in Kidneys From Adriamycin-Induced Injury Mouse Models</title>
<p>Histology confirmed Adriamycin-induced structural kidney injury in mice (<xref ref-type="fig" rid="F4">Figure 4A</xref>), including glomerular sclerosis, tubular atrophy, and interstitial expansion. Severe functional injury was indicated by increased serum creatinine (<xref ref-type="fig" rid="F4">Figure 4B</xref>) and proteinuria (<xref ref-type="fig" rid="F4">Figure 4C</xref>), as well as reduced creatinine clearance (<xref ref-type="fig" rid="F4">Figure 4D</xref>). Numbers of CD4+ CD25+ Tregs were significantly higher in Adriamycin-injured kidneys than in control kidneys (5.1 versus 0.7%) (<xref ref-type="fig" rid="F4">Figure 4E</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p><bold>(A)</bold> Histology of kidney with Adriamycin-induced nephropathy showed severe structural injury, in contrast to healthy control kidney. <bold>(B&#x2013;D)</bold> Serum creatinine, urine protein, and creatinine clearance were assessed in control mice and mice with Adriamycin-induced nephropathy. <bold>(E)</bold> Dot plots from flow cytometry showing numbers of CD4+ CD25+ Tregs isolated from control kidney and kidney with Adriamycin-induced nephropathy. Percentages of cells are indicated within each quadrant. LL, lower left; LR, lower right; Q, quadrant; UL, upper left; UR, upper right.</p></caption>
<graphic xlink:href="fphys-11-00621-g004.tif"/>
</fig>
</sec>
<sec id="S3.SS4">
<title>Tregs Can Protect Against Induced Kidney Injury</title>
<p>To examine whether the influx of Tregs mitigates or aggravates pre-existing kidney damage, we used a mouse model of adoptive cell transfer. CD4+ CD25+ Tregs were isolated from spleens of healthy mice and expanded <italic>in vitro</italic> (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>). Treg cultures of 90% purity were injected via the tail vein into mice with Adriamycin-induced kidney injury (<xref ref-type="fig" rid="F5">Figure 5C</xref>). Kidneys were isolated on day 28 after Adriamycin administration and histology revealed that large numbers of Tregs had been recruited to the injured kidney, such that Tregs were more abundant in injured kidney than in healthy kidney (<xref ref-type="fig" rid="F5">Figure 5D</xref>). Fluorescence imaging (<xref ref-type="fig" rid="F5">Figure 5E</xref>) and histological imaging (<xref ref-type="fig" rid="F5">Figure 5F</xref>) showed that adoptive transfer of Tregs aided recovery of structural defects in the kidney injury model.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p><bold>(A)</bold> Dot plots from flow cytometry showing numbers of CD4+ CD25+ Tregs isolated from spleens of healthy mice. <bold>(B)</bold> Increase in Treg numbers after <italic>in vitro</italic> amplification. <bold>(C)</bold> Dot plots from flow cytometry showing purity of CD4+ CD25+ Tregs after amplification. <bold>(D)</bold> Flow cytometry histogram depicting Treg numbers isolated from mice with Adriamycin-induced nephropathy in which Tregs from healthy donors had been adoptively transferred. <bold>(E)</bold> Fluorescence images of kidneys from control mice, mice with Adriamycin-induced nephropathy, and mice with nephropathy after treatment with Tregs from healthy donors. <bold>(F)</bold> Histological examination suggested that kidney with AN treated with Tregs show less damage than AN. AN, Adriamycin-induced nephropathy.</p></caption>
<graphic xlink:href="fphys-11-00621-g005.tif"/>
</fig>
</sec>
<sec id="S3.SS5">
<title>M2c Macrophages May Enhance the Therapeutic Effects of Tregs</title>
<p>M2c macrophages may induce Tregs to prevent Adriamycin-induced injury in mice (<xref ref-type="bibr" rid="B16">Kinsey et al., 2012</xref>). Indeed, we found that Tregs co-cultured with M2c macrophages showed significant up-regulation of chemokines CCR2, CCR5, CCR7, CD62L, CX3CR1 at the mRNA level (<xref ref-type="fig" rid="F6">Figures 6A&#x2013;C</xref>) and protein level (<xref ref-type="fig" rid="F6">Figures 6B,C</xref>). M2c macrophages may promote the protective effects of Tregs in kidney by increasing expression of these chemokines.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p><bold>(A)</bold> Heatmap showing expression of 16 chemokines in Tregs cultured alone or together with M2c macrophages. <bold>(B,C)</bold> Western blot validation of the chemokine up-regulation observed in panel. M, M2c macrophages; T, regulatory T cells. &#x002A;<italic>P</italic> &#x003C; 0.05 versus M2c macrophages.</p></caption>
<graphic xlink:href="fphys-11-00621-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="S4">
<title>Discussion</title>
<p>Despite the global health burden due to kidney injury, treatments are seriously lacking. In end-stage renal failure, patients require a kidney transplant. However, because of shortages in donor organs, most of these patients rely on hemodialysis&#x2014;but even this intervention has limited success in improving survival (<xref ref-type="bibr" rid="B17">Lameire et al., 2009</xref>; <xref ref-type="bibr" rid="B21">Ortiz et al., 2014</xref>). In recent years, cell-based therapy in various animal models has shown promise for slowing the progression of kidney disease (<xref ref-type="bibr" rid="B29">Togel and Westenfelder, 2012</xref>). In the present study, we found that genes up-regulated in injured kidney tissue are significantly enriched in immune-related BPs and pathways, especially those associated with Tregs. This suggests that the immune system is activated after kidney injury. Tregs were generally increased in injured kidney tissue, including CKD samples from humans (GSE12682) and mice (GSE102513), AKI samples from mice (GSE12682), and CKD samples from rat (GSE85957). We were unable to find publicly available gene expression profiles of Adriamycin-induced kidney injury. Then we validated the increase of Tregs in mice with Adriamycin-induced kidney injury, a model we selected because of its usefulness in studying the pathogenesis and progression of this condition (<xref ref-type="bibr" rid="B20">Lu et al., 2013</xref>; <xref ref-type="bibr" rid="B4">Cao et al., 2016</xref>) and because it involves inflammatory reactions that mimic those in both AKI and CKD (<xref ref-type="bibr" rid="B6">Chawla and Kimmel, 2012</xref>; <xref ref-type="bibr" rid="B7">Coca et al., 2012</xref>). We further showed that adoptive Treg transfer from healthy mice into Adriamycin-treated animals protected against kidney injury. In addition, we found evidence that M2c macrophages work synergistically with Tregs to combat kidney injury by enhancing expression of chemokines in Tregs, which likely recruits more Tregs to sites of inflammation (<xref ref-type="bibr" rid="B35">Zhang et al., 2009</xref>).</p>
<p>A previous meta-analysis study indicated that cell-based therapies improved renal function and morphology in preclinical models of CKD (<xref ref-type="bibr" rid="B22">Papazova et al., 2015</xref>). Unlike our study, that meta-analysis included mesenchymal stem cells, endothelial progenitor cells, hematopoietic stem cells, and bone marrow cells (<xref ref-type="bibr" rid="B22">Papazova et al., 2015</xref>) so the included studies involved a diversity of disease models. Mesenchymal stem cell-based therapy has been shown to improve renal function and recovery of damaged renal tissues in animal studies (<xref ref-type="bibr" rid="B34">Yun and Lee, 2019</xref>), but it has yet to produce strong positive results in clinical trials (<xref ref-type="bibr" rid="B34">Yun and Lee, 2019</xref>). Most clinical studies using hematopoietic stem cell therapy have focused on lupus nephritis and have lacked a control group or randomization (<xref ref-type="bibr" rid="B9">El-Ansary et al., 2012</xref>; <xref ref-type="bibr" rid="B1">Alchi et al., 2013</xref>). The present study shows, through systematic analysis of different types of kidney injury in different species, that harnessing Tregs may be a strategy to treat kidney disease. We validated this hypothesis using mice with Adriamycin-induced kidney injury. Future work should identify whether other types of immune cells than Tregs also inhibit abnormal immune processes and promote kidney repair (<xref ref-type="bibr" rid="B8">Dong et al., 2019</xref>). If so, combining Tregs with these other cell type(s) may be an even more effective treatment.</p>
<p>Indeed, our own previous work showed that alternatively activated macrophages (M2 phenotype), including M2a and M2c subpopulations, exhibit anti-inflammatory functions <italic>in vitro</italic> and protect against renal injury <italic>in vivo</italic> (<xref ref-type="bibr" rid="B32">Wang et al., 2007</xref>). M2c macrophages appear to protect against renal injury better than M2a macrophages because of their ability to induce Tregs (<xref ref-type="bibr" rid="B20">Lu et al., 2013</xref>). We provide evidence here that M2c macrophages may increase CCR2, CCR5, CCR7, CD62L, and CX3CR1 expression in Tregs. This may be one of the mechanisms by which M2c cells recruit Tregs. Future work should explore whether these macrophages can promote the efficacy of Treg-based kidney therapies.</p>
<p>Although the current study provides data supporting a novel cell-based treatment of kidney injury, it has some limitations. First, we assessed the effects of Tregs on injured kidney purely in morphological terms, so future work should seek to explain the molecular basis of this structural recovery, such has by identifying changes in gene expression, particularly of genes involved in fibrosis. Second, we did not begin to assess the safety of adoptive Treg transfer; future work should verify and extend our adoptive transfer studies by including control animals treated with other cell types such as red blood cells. We suspect that the anti-inflammatory Tregs may induce adverse effects similar to those of immunosuppressive drugs. Those studies should also test Treg therapy in other models of kidney injury.</p>
</sec>
<sec id="S5">
<title>Conclusion</title>
<p>Tregs are a potential candidate for cell-based treatment of kidney disease. The relationship between M2c macrophages and Tregs should be explored as a potential way to increase therapeutic efficacy.</p>
</sec>
<sec id="S6">
<title>Data Availability Statement</title>
<p>All datasets presented in this study are included in the article/<xref ref-type="supplementary-material" rid="TS2">Supplementary Material</xref>.</p>
</sec>
<sec id="S7">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by Guangxi Medical University.</p>
</sec>
<sec id="S8">
<title>Author Contributions</title>
<p>JL and JZ designed and coordinated the study and prepared the manuscript. MC and ZL provided assistance in the design of the study and participated in manuscript preparation. CC and PL participated in data gathering. All authors have read and approved the content of the manuscript.</p>
</sec>
<sec id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This study was supported by the National Natural Science Foundation of China (Grant Nos. 81660132, 81760350, and 81560321), the Young Scientists Fund of the Natural Science Foundation of Guangxi (Grant No. 2017GXNSFBA198043), and the Reserve Cadre Training Program Science Foundation of The Second Affiliated Hospital of Guangxi Medical University (Grant Nos. HBRC201804 and HBRC201805).</p>
</fn>
</fn-group>
<ack>
<p>The authors would like to thank Life-Ontology Biological Technology (Nanning, China) for assisting with bioinformatics analysis.</p>
</ack>
<sec id="S11" sec-type="supplementary material"><title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphys.2020.00621/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphys.2020.00621/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.xlsx" id="TS1" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.xlsx" id="TS2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_3.xlsx" id="TS3" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_4.xlsx" id="TS4" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alchi</surname> <given-names>B.</given-names></name> <name><surname>Jayne</surname> <given-names>D.</given-names></name> <name><surname>Labopin</surname> <given-names>M.</given-names></name> <name><surname>Demin</surname> <given-names>A.</given-names></name> <name><surname>Sergeevicheva</surname> <given-names>V.</given-names></name> <name><surname>Alexander</surname> <given-names>T.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the european group for blood and marrow transplantation registry.</article-title> <source><italic>Lupus</italic></source> <volume>22</volume> <fpage>245</fpage>&#x2013;<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1177/0961203312470729</pub-id> <pub-id pub-id-type="pmid">23257404</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aran</surname> <given-names>D.</given-names></name> <name><surname>Hu</surname> <given-names>Z.</given-names></name> <name><surname>Butte</surname> <given-names>A. J.</given-names></name></person-group> (<year>2017</year>). <article-title>xCell: digitally portraying the tissue cellular heterogeneity landscape.</article-title> <source><italic>Genome Biol.</italic></source> <volume>18</volume>:<issue>220</issue>.</citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bagshaw</surname> <given-names>S. M.</given-names></name> <name><surname>Bellomo</surname> <given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Early diagnosis of acute kidney injury.</article-title> <source><italic>Curr. Opin. Crit. Care</italic></source> <volume>13</volume> <fpage>638</fpage>&#x2013;<lpage>644</lpage>.</citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>Q.</given-names></name> <name><surname>Lu</surname> <given-names>J.</given-names></name> <name><surname>Li</surname> <given-names>Q.</given-names></name> <name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Wang</surname> <given-names>X. M.</given-names></name> <name><surname>Lee</surname> <given-names>V. W.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>CD103+ Dendritic cells elicit CD8+ T cell responses to accelerate kidney injury in adriamycin nephropathy.</article-title> <source><italic>J. Am. Soc. Nephrol.</italic></source> <volume>27</volume> <fpage>1344</fpage>&#x2013;<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1681/asn.2015030229</pub-id> <pub-id pub-id-type="pmid">26376858</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Charoentong</surname> <given-names>P.</given-names></name> <name><surname>Finotello</surname> <given-names>F.</given-names></name> <name><surname>Angelova</surname> <given-names>M.</given-names></name> <name><surname>Mayer</surname> <given-names>C.</given-names></name> <name><surname>Efremova</surname> <given-names>M.</given-names></name> <name><surname>Rieder</surname> <given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.</article-title> <source><italic>Cell Rep.</italic></source> <volume>18</volume> <fpage>248</fpage>&#x2013;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.019</pub-id> <pub-id pub-id-type="pmid">28052254</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname> <given-names>L. S.</given-names></name> <name><surname>Kimmel</surname> <given-names>P. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Acute kidney injury and chronic kidney disease: an integrated clinical syndrome.</article-title> <source><italic>Kidney Int.</italic></source> <volume>82</volume> <fpage>516</fpage>&#x2013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2012.208</pub-id> <pub-id pub-id-type="pmid">22673882</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coca</surname> <given-names>S. G.</given-names></name> <name><surname>Singanamala</surname> <given-names>S.</given-names></name> <name><surname>Parikh</surname> <given-names>C. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.</article-title> <source><italic>Kidney Int.</italic></source> <volume>81</volume> <fpage>442</fpage>&#x2013;<lpage>448</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2011.379</pub-id> <pub-id pub-id-type="pmid">22113526</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>Q.</given-names></name> <name><surname>Cai</surname> <given-names>C.</given-names></name> <name><surname>Gao</surname> <given-names>F.</given-names></name> <name><surname>Chen</surname> <given-names>P.</given-names></name> <name><surname>Gong</surname> <given-names>W.</given-names></name> <name><surname>Shen</surname> <given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Defective Treg response in acute kidney injury was caused by a reduction in TIM-3(+) Treg cells.</article-title> <source><italic>Immunol. Invest.</italic></source> <volume>48</volume> <fpage>27</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1080/08820139.2018.1493497</pub-id> <pub-id pub-id-type="pmid">29985717</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Ansary</surname> <given-names>M.</given-names></name> <name><surname>Saadi</surname> <given-names>G.</given-names></name> <name><surname>Abd El-Hamid</surname> <given-names>S. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Mesenchymal stem cells are a rescue approach for recovery of deteriorating kidney function.</article-title> <source><italic>Nephrology</italic></source> <volume>17</volume> <fpage>650</fpage>&#x2013;<lpage>657</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1797.2012.01622.x</pub-id> <pub-id pub-id-type="pmid">22640266</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname> <given-names>Y.</given-names></name> <name><surname>Tian</surname> <given-names>X.</given-names></name> <name><surname>Bai</surname> <given-names>S.</given-names></name> <name><surname>Fan</surname> <given-names>J.</given-names></name> <name><surname>Hou</surname> <given-names>W.</given-names></name> <name><surname>Tong</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway.</article-title> <source><italic>Int. J. Mol. Med.</italic></source> <volume>30</volume> <fpage>85</fpage>&#x2013;<lpage>92</lpage>.</citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname> <given-names>S. D. S.</given-names></name> <name><surname>Roderick</surname> <given-names>P. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Kidney disease in the global burden of disease study 2017.</article-title> <source><italic>Nat. Rev. Nephrol.</italic></source> <volume>15</volume> <fpage>193</fpage>&#x2013;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1038/s41581-019-0120-0</pub-id> <pub-id pub-id-type="pmid">30723305</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Godec</surname> <given-names>J.</given-names></name> <name><surname>Tan</surname> <given-names>Y.</given-names></name> <name><surname>Liberzon</surname> <given-names>A.</given-names></name> <name><surname>Tamayo</surname> <given-names>P.</given-names></name> <name><surname>Bhattacharya</surname> <given-names>S.</given-names></name> <name><surname>Butte</surname> <given-names>A. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation.</article-title> <source><italic>Immunity</italic></source> <volume>44</volume> <fpage>194</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.12.006</pub-id> <pub-id pub-id-type="pmid">26795250</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iseki</surname> <given-names>K.</given-names></name></person-group> (<year>2005</year>). <article-title>Factors influencing the development of end-stage renal disease.</article-title> <source><italic>Clin. Exp. Nephrol.</italic></source> <volume>9</volume> <fpage>5</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s10157-005-0341-3</pub-id> <pub-id pub-id-type="pmid">15830267</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname> <given-names>V.</given-names></name> <name><surname>Garcia-Garcia</surname> <given-names>G.</given-names></name> <name><surname>Iseki</surname> <given-names>K.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Naicker</surname> <given-names>S.</given-names></name> <name><surname>Plattner</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Chronic kidney disease: global dimension and perspectives.</article-title> <source><italic>Lancet</italic></source> <volume>382</volume> <fpage>260</fpage>&#x2013;<lpage>272</lpage>.</citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kazancioglu</surname> <given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Risk factors for chronic kidney disease: an update.</article-title> <source><italic>Kidney Int. Suppl.</italic></source> <volume>3</volume> <fpage>368</fpage>&#x2013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1038/kisup.2013.79</pub-id> <pub-id pub-id-type="pmid">25019021</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinsey</surname> <given-names>G. R.</given-names></name> <name><surname>Huang</surname> <given-names>L.</given-names></name> <name><surname>Jaworska</surname> <given-names>K.</given-names></name> <name><surname>Khutsishvili</surname> <given-names>K.</given-names></name> <name><surname>Becker</surname> <given-names>D. A.</given-names></name> <name><surname>Ye</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection.</article-title> <source><italic>J. Am. Soc. Nephrol.</italic></source> <volume>23</volume> <fpage>1528</fpage>&#x2013;<lpage>1537</lpage>. <pub-id pub-id-type="doi">10.1681/asn.2012010070</pub-id> <pub-id pub-id-type="pmid">22835488</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lameire</surname> <given-names>N.</given-names></name> <name><surname>Van Biesen</surname> <given-names>W.</given-names></name> <name><surname>Vanholder</surname> <given-names>R.</given-names></name></person-group> (<year>2009</year>). <article-title>Did 20 years of technological innovations in hemodialysis contribute to better patient outcomes?</article-title> <source><italic>Clin. J. Am. Soc. Nephrol.</italic></source> <volume>4</volume>(<issue>Suppl. 1</issue>), <fpage>S30</fpage>&#x2013;<lpage>S40</lpage>.</citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lentine</surname> <given-names>K. L.</given-names></name> <name><surname>Kasiske</surname> <given-names>B. L.</given-names></name> <name><surname>Levey</surname> <given-names>A. S.</given-names></name> <name><surname>Adams</surname> <given-names>P. L.</given-names></name> <name><surname>Alberu</surname> <given-names>J.</given-names></name> <name><surname>Bakr</surname> <given-names>M. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Summary of kidney disease: improving global outcomes (KDIGO) clinical practice guideline on the evaluation and care of living kidney donors.</article-title> <source><italic>Transplantation</italic></source> <volume>101</volume> <fpage>1783</fpage>&#x2013;<lpage>1792</lpage>. <pub-id pub-id-type="doi">10.1097/tp.0000000000001770</pub-id> <pub-id pub-id-type="pmid">28737659</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liangos</surname> <given-names>O.</given-names></name> <name><surname>Wald</surname> <given-names>R.</given-names></name> <name><surname>O&#x2019;bell</surname> <given-names>J. W.</given-names></name> <name><surname>Price</surname> <given-names>L.</given-names></name> <name><surname>Pereira</surname> <given-names>B. J.</given-names></name> <name><surname>Jaber</surname> <given-names>B. L.</given-names></name></person-group> (<year>2006</year>). <article-title>Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey.</article-title> <source><italic>Clin. J. Am. Soc. Nephrol.</italic></source> <volume>1</volume> <fpage>43</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.2215/cjn.00220605</pub-id> <pub-id pub-id-type="pmid">17699189</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>J.</given-names></name> <name><surname>Cao</surname> <given-names>Q.</given-names></name> <name><surname>Zheng</surname> <given-names>D.</given-names></name> <name><surname>Sun</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>C.</given-names></name> <name><surname>Yu</surname> <given-names>X.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease.</article-title> <source><italic>Kidney Int.</italic></source> <volume>84</volume> <fpage>745</fpage>&#x2013;<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2013.135</pub-id> <pub-id pub-id-type="pmid">23636175</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname> <given-names>A.</given-names></name> <name><surname>Covic</surname> <given-names>A.</given-names></name> <name><surname>Fliser</surname> <given-names>D.</given-names></name> <name><surname>Fouque</surname> <given-names>D.</given-names></name> <name><surname>Goldsmith</surname> <given-names>D.</given-names></name> <name><surname>Kanbay</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure.</article-title> <source><italic>Lancet</italic></source> <volume>383</volume> <fpage>1831</fpage>&#x2013;<lpage>1843</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(14)60384-6</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papazova</surname> <given-names>D. A.</given-names></name> <name><surname>Oosterhuis</surname> <given-names>N. R.</given-names></name> <name><surname>Gremmels</surname> <given-names>H.</given-names></name> <name><surname>Van Koppen</surname> <given-names>A.</given-names></name> <name><surname>Joles</surname> <given-names>J. A.</given-names></name> <name><surname>Verhaar</surname> <given-names>M. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis.</article-title> <source><italic>Dis. Model. Mech.</italic></source> <volume>8</volume> <fpage>281</fpage>&#x2013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.017699</pub-id> <pub-id pub-id-type="pmid">25633980</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pavkovic</surname> <given-names>M.</given-names></name> <name><surname>Riefke</surname> <given-names>B.</given-names></name> <name><surname>Gutberlet</surname> <given-names>K.</given-names></name> <name><surname>Raschke</surname> <given-names>M.</given-names></name> <name><surname>Ellinger-Ziegelbauer</surname> <given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>Comparison of the mesoscale discovery and luminex multiplex platforms for measurement of urinary biomarkers in a cisplatin rat kidney injury model.</article-title> <source><italic>J. Pharmacol. Toxicol. Methods</italic></source> <volume>69</volume> <fpage>196</fpage>&#x2013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.vascn.2013.11.003</pub-id> <pub-id pub-id-type="pmid">24333954</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname> <given-names>M. E.</given-names></name> <name><surname>Phipson</surname> <given-names>B.</given-names></name> <name><surname>Wu</surname> <given-names>D.</given-names></name> <name><surname>Hu</surname> <given-names>Y.</given-names></name> <name><surname>Law</surname> <given-names>C. W.</given-names></name> <name><surname>Shi</surname> <given-names>W.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>43</volume>:<issue>e47</issue>. <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id> <pub-id pub-id-type="pmid">25605792</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>Y.</given-names></name> <name><surname>Yanagita</surname> <given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Immune cells and inflammation in AKI to CKD progression.</article-title> <source><italic>Am. J. Physiol. Renal Physiol.</italic></source> <volume>315</volume> <fpage>F1501</fpage>&#x2013;<lpage>F1512</lpage>.</citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Si</surname> <given-names>H.</given-names></name> <name><surname>Banga</surname> <given-names>R. S.</given-names></name> <name><surname>Kapitsinou</surname> <given-names>P.</given-names></name> <name><surname>Ramaiah</surname> <given-names>M.</given-names></name> <name><surname>Lawrence</surname> <given-names>J.</given-names></name> <name><surname>Kambhampati</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Human and murine kidneys show gender- and species-specific gene expression differences in response to injury.</article-title> <source><italic>PLoS One</italic></source> <volume>4</volume>:<issue>e4802</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0004802</pub-id> <pub-id pub-id-type="pmid">19277126</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A.</given-names></name> <name><surname>Tamayo</surname> <given-names>P.</given-names></name> <name><surname>Mootha</surname> <given-names>V. K.</given-names></name> <name><surname>Mukherjee</surname> <given-names>S.</given-names></name> <name><surname>Ebert</surname> <given-names>B. L.</given-names></name> <name><surname>Gillette</surname> <given-names>M. A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>102</volume> <fpage>15545</fpage>&#x2013;<lpage>15550</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id> <pub-id pub-id-type="pmid">16199517</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swaminathan</surname> <given-names>M.</given-names></name> <name><surname>Stafford-Smith</surname> <given-names>M.</given-names></name> <name><surname>Chertow</surname> <given-names>G. M.</given-names></name> <name><surname>Warnock</surname> <given-names>D. G.</given-names></name> <name><surname>Paragamian</surname> <given-names>V.</given-names></name> <name><surname>Brenner</surname> <given-names>R. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery.</article-title> <source><italic>J. Am. Soc. Nephrol.</italic></source> <volume>29</volume> <fpage>260</fpage>&#x2013;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1681/asn.2016101150</pub-id> <pub-id pub-id-type="pmid">29038286</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Togel</surname> <given-names>F. E.</given-names></name> <name><surname>Westenfelder</surname> <given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Kidney protection and regeneration following acute injury: progress through stem cell therapy.</article-title> <source><italic>Am. J. Kidney Dis.</italic></source> <volume>60</volume> <fpage>1012</fpage>&#x2013;<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2012.08.034</pub-id> <pub-id pub-id-type="pmid">23036928</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Koppen</surname> <given-names>A.</given-names></name> <name><surname>Joles</surname> <given-names>J. A.</given-names></name> <name><surname>Bongartz</surname> <given-names>L. G.</given-names></name> <name><surname>Van Den Brandt</surname> <given-names>J.</given-names></name> <name><surname>Reichardt</surname> <given-names>H. M.</given-names></name> <name><surname>Goldschmeding</surname> <given-names>R.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Healthy bone marrow cells reduce progression of kidney failure better than CKD bone marrow cells in rats with established chronic kidney disease.</article-title> <source><italic>Cell Transpl.</italic></source> <volume>21</volume> <fpage>2299</fpage>&#x2013;<lpage>2312</lpage>. <pub-id pub-id-type="doi">10.3727/096368912x636795</pub-id> <pub-id pub-id-type="pmid">23231961</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vandenbussche</surname> <given-names>C.</given-names></name> <name><surname>Van Der Hauwaert</surname> <given-names>C.</given-names></name> <name><surname>Dewaeles</surname> <given-names>E.</given-names></name> <name><surname>Franczak</surname> <given-names>J.</given-names></name> <name><surname>Hennino</surname> <given-names>M. F.</given-names></name> <name><surname>Gnemmi</surname> <given-names>V.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation.</article-title> <source><italic>Arch. Toxicol.</italic></source> <volume>92</volume> <fpage>1539</fpage>&#x2013;<lpage>1550</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-018-2158-3</pub-id> <pub-id pub-id-type="pmid">29362864</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>Y. P.</given-names></name> <name><surname>Zheng</surname> <given-names>G.</given-names></name> <name><surname>Lee</surname> <given-names>V. W.</given-names></name> <name><surname>Ouyang</surname> <given-names>L.</given-names></name> <name><surname>Chang</surname> <given-names>D. H.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease.</article-title> <source><italic>Kidney Int.</italic></source> <volume>72</volume> <fpage>290</fpage>&#x2013;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ki.5002275</pub-id> <pub-id pub-id-type="pmid">17440493</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G.</given-names></name> <name><surname>Wang</surname> <given-names>L. G.</given-names></name> <name><surname>Han</surname> <given-names>Y.</given-names></name> <name><surname>He</surname> <given-names>Q. Y.</given-names></name></person-group> (<year>2012</year>). <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters.</article-title> <source><italic>OMICS</italic></source> <volume>16</volume> <fpage>284</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id> <pub-id pub-id-type="pmid">22455463</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname> <given-names>C. W.</given-names></name> <name><surname>Lee</surname> <given-names>S. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Potential and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for acute/chronic kidney disease.</article-title> <source><italic>Int. J. Mol. Sci.</italic></source> <volume>20</volume>:<issue>1619</issue>. <pub-id pub-id-type="doi">10.3390/ijms20071619</pub-id> <pub-id pub-id-type="pmid">30939749</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>N.</given-names></name> <name><surname>Schroppel</surname> <given-names>B.</given-names></name> <name><surname>Lal</surname> <given-names>G.</given-names></name> <name><surname>Jakubzick</surname> <given-names>C.</given-names></name> <name><surname>Mao</surname> <given-names>X.</given-names></name> <name><surname>Chen</surname> <given-names>D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response.</article-title> <source><italic>Immunity</italic></source> <volume>30</volume> <fpage>458</fpage>&#x2013;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2008.12.022</pub-id> <pub-id pub-id-type="pmid">19303390</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>X. Y.</given-names></name> <name><surname>Urbieta-Caceres</surname> <given-names>V.</given-names></name> <name><surname>Krier</surname> <given-names>J. D.</given-names></name> <name><surname>Textor</surname> <given-names>S. C.</given-names></name> <name><surname>Lerman</surname> <given-names>A.</given-names></name> <name><surname>Lerman</surname> <given-names>L. O.</given-names></name></person-group> (<year>2013</year>). <article-title>Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms.</article-title> <source><italic>Stem Cells</italic></source> <volume>31</volume> <fpage>117</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1002/stem.1263</pub-id> <pub-id pub-id-type="pmid">23097349</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="footnote1">
<label>1</label>
<p><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">www.ncbi.nlm.nih.gov/geo</ext-link></p></fn>
<fn id="footnote2">
<label>2</label>
<p><ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea">http://www.broadinstitute.org/gsea</ext-link></p></fn>
<fn id="footnote3">
<label>3</label>
<p><ext-link ext-link-type="uri" xlink:href="http://xcell.ucsf.edu/">http://xcell.ucsf.edu/</ext-link></p></fn>
</fn-group>
</back>
</article>
